Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively stimulates growth hormone release from the anterior pituitary. Originally developed through research conducted by Novo Nordisk, Ipamorelin has become one of the most widely studied compounds in growth hormone signaling research.
Ipamorelin is distinguished by its selective growth hormone releasing activity. Published research has demonstrated that it stimulates GH release with minimal impact on cortisol, prolactin, or ACTH levels compared to earlier growth hormone secretagogues.
This selective profile has made Ipamorelin a compound of interest in controlled research settings where isolating growth hormone activity from broader endocrine stimulation is important.
Molecular formula: C38H49N9O5
Molecular weight: 711.85 g/mol
Ipamorelin acts primarily on the ghrelin receptor (GHS-R1a) located in the pituitary gland. Activation of this receptor stimulates the release of stored growth hormone in a pulsatile manner that resembles natural physiological secretion patterns.
Unlike GHRH analogs that promote growth hormone synthesis over time, Ipamorelin primarily promotes the release of existing GH stores, contributing to its shorter-duration signaling profile.
Published research has explored Ipamorelin in studies involving growth hormone release kinetics, body composition, bone metabolism, and age-related declines in GH signaling. Experimental models have also examined its effects on bone formation markers and tissue recovery pathways.
Researchers continue to investigate Ipamorelin within broader endocrine and metabolic research, particularly in studies focused on pulsatile GH release and recovery-related signaling pathways.
Ipamorelin and CJC-1295 are frequently studied together due to their complementary mechanisms of action. Ipamorelin promotes short-duration pulsatile growth hormone release, while CJC-1295 supports prolonged stimulation of growth hormone production and signaling.
Combined research protocols often investigate whether maintaining an elevated GH baseline alongside pulsatile release patterns more closely reflects natural physiological growth hormone activity than either compound alone.
Ipamorelin is supplied as a lyophilized powder for research purposes. Store at -20°C prior to reconstitution. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and avoid repeated freeze-thaw cycles.
At White Label Research, Ipamorelin undergoes third-party HPLC and mass spectrometry testing to verify identity and purity. Certificates of analysis are available on the product page. Our standard threshold is ≥99% purity.
